PEAK6
ALNY icon

PEAK6’s Alnylam Pharmaceuticals ALNY Stock Holding History

PEAK6’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.18M Buy
+9,600
New +$3.27M 0.01% 1121
2025
Q4 		– Sell
-700
Closed -$319K – 2790
2025
Q3 		$319K Sell
700
-600
-46% -$244K ﹤0.01% 2313
2025
Q2 		$424K Sell
1,300
-12,000
-90% -$3.32M ﹤0.01% 2191
2025
Q1 		$3.59M Sell
13,300
-34,400
-72% -$8.84M 0.01% 1104
2024
Q4 		$11.2M Buy
+47,700
New +$12.5M 0.02% 525

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PEAK6's ALNY Position: Q1 2026 in Review

PEAK6 increased its Alnylam Pharmaceuticals (ALNY) stake by 485,700% in Q1 2026, buying an estimated $3.31M and bringing the position to 9,716 shares worth $3.21M. The position accounts for 0.01% of the portfolio, ranked #1118.

PEAK6 first reported a position in ALNY in Q4 2024 and has held it in 5 quarters since. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • PEAK6 held 9,716 shares of Alnylam Pharmaceuticals worth $3.21M as of Q1 2026.
  • PEAK6 bought 9,714 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $3.31M.
  • Alnylam Pharmaceuticals made up 0.01% of PEAK6's portfolio in Q1 2026, its #1118 holding.
  • PEAK6 first reported a position in Alnylam Pharmaceuticals in Q4 2024 and has held it in 5 quarters since.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on PEAK6's 13F filing for Q1 2026, filed 14 May 2026.